129 related articles for article (PubMed ID: 37547578)
1. Antibody responses following the surge of SARS-CoV-2 Omicron infection among patients with systemic autoimmune rheumatic diseases.
Xiang N; Li YJ; Liu MY; Wu QQ; Zhang YX; Jin HZ; Wang Q; Li YW; Tong DL; Xue T; Jin TC; Bao W; Chen Z
Rheumatol Adv Pract; 2023; 7(2):rkad064. PubMed ID: 37547578
[TBL] [Abstract][Full Text] [Related]
2. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study.
Qian G; Wang X; Patel NJ; Kawano Y; Fu X; Cook CE; Vanni KMM; Kowalski EN; Banasiak EP; Bade KJ; Srivatsan S; Williams ZK; Todd DJ; Weinblatt ME; Wallace ZS; Sparks JA
medRxiv; 2022 Oct; ():. PubMed ID: 36324801
[TBL] [Abstract][Full Text] [Related]
3. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave to Omicron.
Kawano Y; Patel NJ; Wang X; Cook CE; Vanni KMM; Kowalski EN; Banasiak EP; Qian G; DiIorio M; Hsu TYT; Weinblatt ME; Todd DJ; Wallace ZS; Sparks JA
medRxiv; 2022 Jun; ():. PubMed ID: 35765565
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases and Serum Antibody Changes Post-Omicron Variant Infection.
Zhang X; Li Y; Dai C; Chu Y; Luan C; Wang G
Rheumatol Ther; 2024 Feb; 11(1):191-200. PubMed ID: 38175331
[TBL] [Abstract][Full Text] [Related]
5. Detection of SARS-CoV-2 antibodies after confirmed Omicron BA.1 and presumed BA.4/5 infections using Abbott ARCHITECT and Panbio assays.
Boler M; Anderson M; Rodgers M; Parumoottil J; Olivo A; Harris B; Stec M; Gosha A; Behun D; Holzmayer V; Anderson A; Greenholt E; Fortney T; Almaraz E; Cloherty G; Landay A; Moy J
IJID Reg; 2023 Jun; 7():277-280. PubMed ID: 37234563
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
[TBL] [Abstract][Full Text] [Related]
7. Impaired neutralizing antibodies and preserved cellular immunogenicity against SARS-CoV-2 in systemic autoimmune rheumatic diseases.
Intapiboon P; Uae-Areewongsa P; Ongarj J; Sophonmanee R; Seepathomnarong P; Seeyankem B; Surasombatpattana S; Pinpathomrat N
NPJ Vaccines; 2022 Nov; 7(1):149. PubMed ID: 36379939
[TBL] [Abstract][Full Text] [Related]
8. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.
Bruel T; Pinaud L; Tondeur L; Planas D; Staropoli I; Porrot F; Guivel-Benhassine F; Attia M; Pelleau S; Woudenberg T; Duru C; Koffi AD; Castelain S; Fernandes-Pellerin S; Jolly N; De Facci LP; Roux E; Ungeheuer MN; Van Der Werf S; White M; Schwartz O; Fontanet A
EClinicalMedicine; 2022 Sep; 51():101576. PubMed ID: 35891947
[TBL] [Abstract][Full Text] [Related]
9. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response in adults with predominantly antibody deficiency.
Zhang AM; Elmoursi A; DiGiacomo DV; Zhou B; Tandon M; Hong JS; Yang NJ; Ong MS; Dighe AS; Berrios C; Poznansky MC; Iafrate AJ; Naranbhai V; Balazs A; Pillai S; Farmer JR; Barmettler S
J Allergy Clin Immunol Glob; 2024 May; 3(2):100234. PubMed ID: 38544577
[TBL] [Abstract][Full Text] [Related]
10. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
11. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
[TBL] [Abstract][Full Text] [Related]
12. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
[TBL] [Abstract][Full Text] [Related]
14. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L
Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections.
Saade C; Brengel-Pesce K; Gaymard A; Trabaud MA; Destras G; Oriol G; Cheynet V; Debombourg M; Mokdad B; Billaud G; Oblette A; Créhalet H; Giannoli JM; Garrigou C; Generenaz L; Compagnon C; Boibieux A; Lina B; Morfin F; Pozzetto B; Josset L; Trouillet-Assant S; Bal A
Emerg Microbes Infect; 2022 Dec; 11(1):2423-2432. PubMed ID: 36098494
[TBL] [Abstract][Full Text] [Related]
17. Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients.
Liu Y; Zhao L; Wang L; Li Y; Wang L; Yu B; Hu D; Weng H; Guo J; Yang J; Yang J; Yu X
Heliyon; 2023 Jul; 9(7):e18093. PubMed ID: 37519697
[TBL] [Abstract][Full Text] [Related]
18. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study.
Kim WJ; Choi SH; Park JY; Song JS; Chung JW; Choi ST
Ann Rheum Dis; 2022 Nov; 81(11):1585-1593. PubMed ID: 35878999
[TBL] [Abstract][Full Text] [Related]
20. Impacts of delta and omicron variants on inactivated SARS-CoV-2 vaccine-induced T cell responses in patients with autoimmune diseases and healthy controls.
Wang S; Li J; Wang S; Ye Y; Li M; Liu Y; Chen B; Lai Y; Li L; Zhuang L; Peng S; Yang N; Zhang H; Xiao H
Clin Transl Med; 2023 Jan; 13(1):e1171. PubMed ID: 36639826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
